Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells, EGFR BATs, EGFRBi-Armed Autologous T Cells(Barbara Ann Karmanos Cancer Institute) |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gliosarcoma | Phase 2 | - | 01 Aug 2015 | |
Recurrent Glioblastoma | Phase 2 | - | 01 Aug 2015 | |
Pancreatic Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Malignant neoplasm of large intestine | Phase 1 | US | 17 Aug 2011 | |
Recurrent Colon Cancer | Phase 1 | US | 17 Aug 2011 |
Phase 1/2 | 7 | tnfykklptl(qbjerdrkyy) = cpdfsftkzz tsuqdrgjte (tdiaxxyhxp ) View more | Positive | 10 Jun 2020 | |||
Phase 1/2 | 20 | bispecific antibody armed T cells | ypjvftmwvx(cbonvtanhh) = mqmuzubylp uhfrhbavbk (bdqqhpievt ) View more | Positive | 03 Jun 2019 | ||
Phase 1 | 6 | uehcreweew(vkmvqduxrt) = grade 2= 1 pt, grade 3= 1 pt uczymsolwx (wjwgqnvlmb ) View more | - | 20 May 2012 |